Tomomi Takiguchi

Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study

K. Suzuki, Takeharu Yamanaka, Hiroki Hashimoto et al. · Annals of Oncology · 2016 · 97 citations · Full text

Oncology, Metronomic Therapy, Pharmacology +6

A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy

Takako Yanai, Satoru Iwasa, Hironobu Hashimoto et al. · International Journal of Clinical Oncology · 2017 · 71 citations

Oncology, Pharmacology, Emetogenic Cisplatin-based Chemotherapy +5

Factors Exacerbating Peripheral Neuropathy Induced by Paclitaxel Plus Carboplatin in Non-small Cell Lung Cancer

Kazuyoshi Kawakami, Takashi Tunoda, Tomomi Takiguchi et al. · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · 2012 · 40 citations · Full text

Peripheral Neuropathy Induced, Oncology, Medicine +14

Palonosetron (PALO) versus granisetron (GRA) in the triplet regimen with dexamethasone (DEX) and aprepitant (APR) for preventing chemotherapy-induced nausea and vomiting (CINV) in patients (pts) receiving highly emetogenic chemotherapy (HEC) with cisplatin (CDDP): A randomized, double-blind, phase III trial.

Hironobu Hashimoto, Takeharu Yamanaka, Yasuhiro Shimada et al. · Journal of Clinical Oncology · 2013 · 17 citations

Emetogenic Chemotherapy, Oncology, Primary Endpoint +11

Self-Reported Adherence to Trifluridine and Tipiracil Hydrochloride for Metastatic Colorectal Cancer: A Retrospective Cohort Study

Kazuo Sugita, Kazuyoshi Kawakami, Takashi Yokokawa et al. · Oncology · 2016 · 17 citations